…to warnings issued by the World Health Organization and the United Nations. Molsid, a spin-off from the University of Lyon – ENS created in 2018, is developing a test kit…
…approval in the United States with the indication for the GBM. I am really grateful that RZ-001 earned the opportunity to potentially fulfill the unmet needs of GBM patients. Through…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high…
…gene editing treatment for a rare form of blindness, outside of the United States. The deal totals $170M (€137M), including an upfront payment of $105M (€85M) and $65M (€52M) in…
…to severe forms of the condition receive this treatment in the United States—and even fewer people do in Europe. BioLingus, a Swiss biotech, is also working on developing a needle-free…
…the abuse epidemic in the United States,” continued Menet. “The Confo screen assay is revolutionary: it’s a simple binding assay that can predict the biological activity of a drug candidate…
…results of Eisai’s AD research over the past 40 years have been recognized and delivered to people living with this disease in the United States,” said Haruo Naito, chief executive…
…with plaque psoriasis in the United States are untreated or undertreated. “The FDA approval of a new oral treatment is exciting news for the psoriasis community. We welcome this new…
…a vaccine for cattle, in a Reuters interview. The United States Department of Agriculture (USDA) is also working in tandem with universities and research organizations to better understand the spread…
…of meals from upcycled vegetables. According to the United Nations Food and Agriculture Organisation, a staggering 1.3 billion tons of food is wasted every year, across the world. That’s one-third of all food produced…
…creation meets certain eligibility requirements. For example, in the United States, the US Patent & Trademark Office set forth five elements for patentability. To qualify, an invention must fall under…
…of the deal were not disclosed. Additionally, GLP-1 agonists have been eyed by biopharmas of late. American pharma Regeneron has united with China-based Hansoh Pharma to nab the latter’s GLP-1/GIP…